+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
GalNAc-based Drug Market - Global Forecast 2026-2032- Product Image
GalNAc-based Drug Market - Global Forecast 2026-2032- Product Image
Sale

GalNAc-based Drug Market - Global Forecast 2026-2032

  • Report

  • 199 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6121135
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The GalNAc-based Drug Market is projected to reach USD 914.25 Million in 2026. It is expected to continue growing at a CAGR of 7.40%, reaching USD 1.39 Billion by 2032.

GalNAc-Based Drugs: Executive Overview

GalNAc-based drugs use N-acetylgalactosamine ligands to direct therapeutics toward hepatocytes through the asialoglycoprotein receptor. This approach has become an important platform for liver-focused drug delivery, particularly for nucleic acid medicines such as small interfering RNA. Its value proposition includes tissue-selective uptake, potent target suppression, and the possibility of less frequent dosing than some conventional systemic therapies. Development priorities increasingly center on durable pharmacology, clinically meaningful outcomes, manufacturing consistency, and safe expansion into additional disease areas.

How Liver-Targeted Delivery Is Reshaping Drug Development

The landscape is shifting from proof-of-concept delivery toward platform optimization and broader clinical validation. Researchers are refining ligand valency, linker chemistry, conjugation methods, and sequence design to improve cellular uptake and reduce off-target exposure. These advances are supporting investigation across rare diseases, cardiometabolic conditions, infectious diseases, and other disorders in which hepatic gene modulation may influence systemic biology. At the same time, developers face heightened expectations for long-term safety monitoring, immune effects, repeat-dose tolerability, and evidence that biomarker changes translate into durable patient benefit.

Artificial Intelligence Accelerates Design, Selection, and Development

Artificial intelligence can strengthen the GalNAc-based drug value chain by helping identify disease-relevant targets, predict RNA sequence performance, optimize ligand and linker combinations, and prioritize candidates for laboratory testing. Machine-learning systems may also support analysis of pharmacokinetic, pharmacodynamic, transcriptomic, and safety datasets, improving the identification of responders and potential toxicity signals. Its cumulative impact depends on high-quality, standardized datasets and experimental confirmation: models can narrow decision spaces, but they do not replace receptor biology, toxicology, clinical judgment, or regulatory evidence. Governance, interpretability, and secure handling of patient data remain essential.

Regional Priorities Across North America, Latin America, Europe, the Middle East, Africa, and Asia-Pacific

North America remains influential through advanced nucleic acid research, specialized clinical infrastructure, and established regulatory experience. Europe emphasizes translational science, cross-border clinical evaluation, and alignment with rigorous medicines oversight, while the European Union benefits from coordinated scientific and regulatory mechanisms. Asia-Pacific combines strong capabilities in RNA research and biomanufacturing with expanding clinical-trial networks; Japan, China, South Korea, India, and Australia each contribute distinct scientific or development strengths. Latin America is relevant for patient recruitment, local clinical partnerships, and access planning, with Brazil and Mexico serving as important considerations. The Middle East and Africa require attention to specialized-care capacity, diagnostic availability, supply continuity, and culturally appropriate implementation pathways.

Group-Level Signals Across ASEAN, BRICS, the European Union, G7, GCC, and NATO

ASEAN presents opportunities for coordinated research and clinical development but requires navigation of varied regulatory systems and healthcare access conditions. BRICS members offer substantial scientific, manufacturing, and patient-population capabilities, although regulatory convergence and technology-transfer arrangements differ across countries. The European Union provides a framework for collaborative research and centralized scientific dialogue, while the G7 combines advanced life-science ecosystems with strong expectations for evidence quality, pharmacovigilance, and supply resilience. GCC markets can support specialist-care deployment and regional investment in biotechnology infrastructure. NATO countries may benefit from aligned preparedness, research, and supply-chain discussions, although medicinal-product regulation remains principally national or regional rather than a NATO function.

Country-Level Considerations for Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Russia, South Korea, Spain, the United Kingdom

Australia offers capable clinical research networks and a strong environment for early development. Brazil and Mexico are important for Latin American trials and access planning, with attention to regulatory coordination and healthcare heterogeneity. Canada and the United States combine deep biotechnology expertise with demanding evidence and reimbursement environments. China, Japan, South Korea, and India provide substantial research, manufacturing, and clinical capabilities, while requiring careful navigation of local standards, data rules, and commercialization pathways. France, Germany, Italy, and Spain contribute major European research and healthcare systems within the wider European framework. The United Kingdom remains influential in life-science research and regulatory science. Russia requires careful assessment of regulatory, operational, and supply conditions before development or access decisions.

Actions for Leaders: Build Durable Advantage Around Evidence and Execution

Industry leaders should prioritize targets with a clear biological rationale for hepatic delivery and define clinically relevant endpoints early. Platform programs should use standardized assays for receptor binding, cellular uptake, biodistribution, durability, immunogenicity, and repeat-dose safety. Partnerships with specialized RNA, analytical, manufacturing, and clinical organizations can reduce execution risk, while dual-source planning and rigorous quality systems can strengthen supply resilience. Leaders should also establish AI governance, integrate real-world evidence into lifecycle planning, engage regulators early, and design access strategies that account for diagnostic capacity, treatment frequency, monitoring needs, and regional healthcare differences.

Methodology: Evidence-Based Synthesis of GalNAc Drug Development

This executive summary uses a structured qualitative synthesis focused on the biology, delivery technology, clinical-development practices, regulatory considerations, manufacturing requirements, and geographic implementation factors associated with GalNAc-based drugs. Findings should be validated against peer-reviewed literature, public regulatory documents, clinical-trial registries, product labels where applicable, pharmacovigilance sources, and authoritative health-system publications. Regional, group, and country observations are framed as strategic considerations rather than quantitative market claims. No market estimates, shares, forecasts, or company-specific comparisons are used.

Conclusion: Converting Targeted Hepatic Delivery Into Patient Value

GalNAc-based drugs offer a validated route to selective hepatic delivery and have helped advance nucleic acid therapeutics toward practical clinical use. Future progress will depend less on delivery novelty alone and more on the integration of target selection, durable pharmacology, safety monitoring, scalable manufacturing, regulatory alignment, and equitable implementation. Organizations that combine disciplined translational evidence with responsible AI, regional adaptability, and resilient operations will be better positioned to convert the platform’s biological advantages into sustained patient benefit.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. GalNAc-based Drug Market, by Product Type
7.1. Introduction
7.2. Antisense Oligonucleotide
7.3. Small Interfering Rna
8. GalNAc-based Drug Market, by Indication
8.1. Introduction
8.2. Genetic Disorders
8.2.1. Familial Hypercholesterolemia
8.2.2. Hemophilia
8.3. Metabolic Syndrome
8.3.1. Hyperlipidemia
8.3.2. Obesity
8.3.3. Type 2 Diabetes
8.4. Oncology
8.5. Rare Liver Disease
8.5.1. Hyperbilirubinemia
8.5.2. Hyperoxaluria
8.5.3. Porphyria
9. GalNAc-based Drug Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
9.4. Subcutaneous
10. GalNAc-based Drug Market, by Clinical Trial Phase
10.1. Introduction
10.2. Approved
10.3. Phase I
10.4. Phase Ii
10.5. Phase Iii
10.6. Preclinical
11. GalNAc-based Drug Market, by End User
11.1. Introduction
11.2. Hospitals
11.3. Research Institutions
11.4. Specialty Clinics
12. GalNAc-based Drug Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. GalNAc-based Drug Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. GalNAc-based Drug Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Akcea Therapeutics, Inc.
16.2. Alnylam Pharmaceuticals, Inc.
16.3. Amgen Inc.
16.4. Arcturus Therapeutics Holdings Inc.
16.5. Arrowhead Pharmaceuticals, Inc.
16.6. AstraZeneca plc
16.7. Bayer AG
16.8. Beam Therapeutics Inc.
16.9. BioNTech SE
16.10. CureVac N.V.
16.11. Dicerna Pharmaceuticals, Inc.
16.12. Eli Lilly and Company
16.13. Gilead Sciences, Inc.
16.14. GlaxoSmithKline plc
16.15. Ionis Pharmaceuticals, Inc.
16.16. Merck & Co., Inc.
16.17. Moderna, Inc.
16.18. Novartis AG
16.19. Novo Nordisk A/S
16.20. Pfizer Inc.
16.21. Roche Holding AG
16.22. Sanofi S.A.
16.23. Sarepta Therapeutics, Inc.
16.24. Takeda Development Center Americas, Inc.
16.25. Takeda Pharmaceutical Company Limited
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global GalNAc-based Drug Market, Years Considered for the Study
FIGURE 2. Global GalNAc-based Drug Market, Research Design
FIGURE 3. Global GalNAc-based Drug Market, Research Framework
FIGURE 4. Global GalNAc-based Drug Market, Data Triangulation
FIGURE 5. Global GalNAc-based Drug Market Size, 2017-2032 (USD Million)
FIGURE 6. Global GalNAc-based Drug Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 7. Global GalNAc-based Drug Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global GalNAc-based Drug Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 9. Global GalNAc-based Drug Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global GalNAc-based Drug Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 11. Global GalNAc-based Drug Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global GalNAc-based Drug Market Size, by Clinical Trial Phase, 2025 vs 2032 (%)
FIGURE 13. Global GalNAc-based Drug Market Size, by Clinical Trial Phase, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global GalNAc-based Drug Market Size, by End User, 2025 vs 2032 (%)
FIGURE 15. Global GalNAc-based Drug Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global GalNAc-based Drug Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global GalNAc-based Drug Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global GalNAc-based Drug Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global GalNAc-based Drug Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global GalNAc-based Drug Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global GalNAc-based Drug Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global GalNAc-based Drug Market Segmentation & Coverage
TABLE 2. Global GalNAc-based Drug Market Size, 2017-2032 (USD Million)
TABLE 3. Global GalNAc-based Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 4. Global Antisense Oligonucleotide Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Antisense Oligonucleotide Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Antisense Oligonucleotide Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Small Interfering Rna Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Small Interfering Rna Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Small Interfering Rna Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global GalNAc-based Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 11. Global Genetic Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 12. Global Genetic Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 13. Global Genetic Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 14. Global Familial Hypercholesterolemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Familial Hypercholesterolemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Familial Hypercholesterolemia Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Hemophilia Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Hemophilia Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Hemophilia Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Metabolic Syndrome Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Metabolic Syndrome Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Metabolic Syndrome Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Hyperlipidemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Hyperlipidemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Hyperlipidemia Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Obesity Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Obesity Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Obesity Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Type 2 Diabetes Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Type 2 Diabetes Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Type 2 Diabetes Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Rare Liver Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Rare Liver Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Rare Liver Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Hyperbilirubinemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Hyperbilirubinemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Hyperbilirubinemia Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Hyperoxaluria Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Hyperoxaluria Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Hyperoxaluria Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Porphyria Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Porphyria Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Porphyria Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global GalNAc-based Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 48. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global GalNAc-based Drug Market Size, by Clinical Trial Phase, 2017-2032 (USD Million)
TABLE 58. Global Approved Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Approved Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Approved Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Phase I Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Phase I Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Phase I Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Phase Ii Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Phase Ii Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Phase Ii Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Phase Iii Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Global Phase Iii Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. Global Phase Iii Market Size, by Country, 2017-2032 (USD Million)
TABLE 70. Global Preclinical Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Global Preclinical Market Size, by Group, 2017-2032 (USD Million)
TABLE 72. Global Preclinical Market Size, by Country, 2017-2032 (USD Million)
TABLE 73. Global GalNAc-based Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 74. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 76. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 77. Global Research Institutions Market Size, by Region, 2017-2032 (USD Million)
TABLE 78. Global Research Institutions Market Size, by Group, 2017-2032 (USD Million)
TABLE 79. Global Research Institutions Market Size, by Country, 2017-2032 (USD Million)
TABLE 80. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 81. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 82. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 83. Global GalNAc-based Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 84. Asia-Pacific GalNAc-based Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 85. Asia-Pacific GalNAc-based Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 86. Asia-Pacific GalNAc-based Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 87. Asia-Pacific GalNAc-based Drug Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 88. Asia-Pacific GalNAc-based Drug Market Size, by Metabolic Syndrome, 2017-2032 (USD Million)
TABLE 89. Asia-Pacific GalNAc-based Drug Market Size, by Rare Liver Disease, 2017-2032 (USD Million)
TABLE 90. Asia-Pacific GalNAc-based Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 91. Asia-Pacific GalNAc-based Drug Market Size, by Clinical Trial Phase, 2017-2032 (USD Million)
TABLE 92. Asia-Pacific GalNAc-based Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 93. North America GalNAc-based Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 94. North America GalNAc-based Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 95. North America GalNAc-based Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 96. North America GalNAc-based Drug Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 97. North America GalNAc-based Drug Market Size, by Metabolic Syndrome, 2017-2032 (USD Million)
TABLE 98. North America GalNAc-based Drug Market Size, by Rare Liver Disease, 2017-2032 (USD Million)
TABLE 99. North America GalNAc-based Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 100. North America GalNAc-based Drug Market Size, by Clinical Trial Phase, 2017-2032 (USD Million)
TABLE 101. North America GalNAc-based Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 102. Latin America GalNAc-based Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 103. Latin America GalNAc-based Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 104. Latin America GalNAc-based Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 105. Latin America GalNAc-based Drug Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 106. Latin America GalNAc-based Drug Market Size, by Metabolic Syndrome, 2017-2032 (USD Million)
TABLE 107. Latin America GalNAc-based Drug Market Size, by Rare Liver Disease, 2017-2032 (USD Million)
TABLE 108. Latin America GalNAc-based Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 109. Latin America GalNAc-based Drug Market Size, by Clinical Trial Phase, 2017-2032 (USD Million)
TABLE 110. Latin America GalNAc-based Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 111. Europe GalNAc-based Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 112. Europe GalNAc-based Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 113. Europe GalNAc-based Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 114. Europe GalNAc-based Drug Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 115. Europe GalNAc-based Drug Market Size, by Metabolic Syndrome, 2017-2032 (USD Million)
TABLE 116. Europe GalNAc-based Drug Market Size, by Rare Liver Disease, 2017-2032 (USD Million)
TABLE 117. Europe GalNAc-based Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 118. Europe GalNAc-based Drug Market Size, by Clinical Trial Phase, 2017-2032 (USD Million)
TABLE 119. Europe GalNAc-based Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 120. Middle East GalNAc-based Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 121. Middle East GalNAc-based Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 122. Middle East GalNAc-based Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 123. Middle East GalNAc-based Drug Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 124. Middle East GalNAc-based Drug Market Size, by Metabolic Syndrome, 2017-2032 (USD Million)
TABLE 125. Middle East GalNAc-based Drug Market Size, by Rare Liver Disease, 2017-2032 (USD Million)
TABLE 126. Middle East GalNAc-based Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 127. Middle East GalNAc-based Drug Market Size, by Clinical Trial Phase, 2017-2032 (USD Million)
TABLE 128. Middle East GalNAc-based Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 129. Africa GalNAc-based Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 130. Africa GalNAc-based Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 131. Africa GalNAc-based Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 132. Africa GalNAc-based Drug Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 133. Africa GalNAc-based Drug Market Size, by Metabolic Syndrome, 2017-2032 (USD Million)
TABLE 134. Africa GalNAc-based Drug Market Size, by Rare Liver Disease, 2017-2032 (USD Million)
TABLE 135. Africa GalNAc-based Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 136. Africa GalNAc-based Drug Market Size, by Clinical Trial Phase, 2017-2032 (USD Million)
TABLE 137. Africa GalNAc-based Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 138. Global GalNAc-based Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 139. ASEAN GalNAc-based Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 140. ASEAN GalNAc-based Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 141. ASEAN GalNAc-based Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 142. ASEAN GalNAc-based Drug Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 143. ASEAN GalNAc-based Drug Market Size, by Metabolic Syndrome, 2017-2032 (USD Million)
TABLE 144. ASEAN GalNAc-based Drug Market Size, by Rare Liver Disease, 2017-2032 (USD Million)
TABLE 145. ASEAN GalNAc-based Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 146. ASEAN GalNAc-based Drug Market Size, by Clinical Trial Phase, 2017-2032 (USD Million)
TABLE 147. ASEAN GalNAc-based Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 148. GCC GalNAc-based Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 149. GCC GalNAc-based Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 150. GCC GalNAc-based Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 151. GCC GalNAc-based Drug Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 152. GCC GalNAc-based Drug Market Size, by Metabolic Syndrome, 2017-2032 (USD Million)
TABLE 153. GCC GalNAc-based Drug Market Size, by Rare Liver Disease, 2017-2032 (USD Million)
TABLE 154. GCC GalNAc-based Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 155. GCC GalNAc-based Drug Market Size, by Clinical Trial Phase, 2017-2032 (USD Million)
TABLE 156. GCC GalNAc-based Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 157. European Union GalNAc-based Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 158. European Union GalNAc-based Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 159. European Union GalNAc-based Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 160. European Union GalNAc-based Drug Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 161. European Union GalNAc-based Drug Market Size, by Metabolic Syndrome, 2017-2032 (USD Million)
TABLE 162. European Union GalNAc-based Drug Market Size, by Rare Liver Disease, 2017-2032 (USD Million)
TABLE 163. European Union GalNAc-based Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 164. European Union GalNAc-based Drug Market Size, by Clinical Trial Phase, 2017-2032 (USD Million)
TABLE 165. European Union GalNAc-based Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 166. BRICS GalNAc-based Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 167. BRICS GalNAc-based Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 168. BRICS GalNAc-based Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 169. BRICS GalNAc-based Drug Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 170. BRICS GalNAc-based Drug Market Size, by Metabolic Syndrome, 2017-2032 (USD Million)
TABLE 171. BRICS GalNAc-based Drug Market Size, by Rare Liver Disease, 2017-2032 (USD Million)
TABLE 172. BRICS GalNAc-based Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 173. BRICS GalNAc-based Drug Market Size, by Clinical Trial Phase, 2017-2032 (USD Million)
TABLE 174. BRICS GalNAc-based Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 175. G7 GalNAc-based Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 176. G7 GalNAc-based Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 177. G7 GalNAc-based Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 178. G7 GalNAc-based Drug Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 179. G7 GalNAc-based Drug Market Size, by Metabolic Syndrome, 2017-2032 (USD Million)
TABLE 180. G7 GalNAc-based Drug Market Size, by Rare Liver Disease, 2017-2032 (USD Million)
TABLE 181. G7 GalNAc-based Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 182. G7 GalNAc-based Drug Market Size, by Clinical Trial Phase, 2017-2032 (USD Million)
TABLE 183. G7 GalNAc-based Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 184. NATO GalNAc-based Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 185. NATO GalNAc-based Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 186. NATO GalNAc-based Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 187. NATO GalNAc-based Drug Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 188. NATO GalNAc-based Drug Market Size, by Metabolic Syndrome, 2017-2032 (USD Million)
TABLE 189. NATO GalNAc-based Drug Market Size, by Rare Liver Disease, 2017-2032 (USD Million)
TABLE 190. NATO GalNAc-based Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 191. NATO GalNAc-based Drug Market Size, by Clinical Trial Phase, 2017-2032 (USD Million)
TABLE 192. NATO GalNAc-based Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 193. Global GalNAc-based Drug Market Size, by Country, 2017-2032 (USD Million)
TABLE 194. United States GalNAc-based Drug Market Size, 2017-2032 (USD Million)
TABLE 195. United States GalNAc-based Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 196. United States GalNAc-based Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 197. United States GalNAc-based Drug Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 198. United States GalNAc-based Drug Market Size, by Metabolic Syndrome, 2017-2032 (USD Million)
TABLE 199. United States GalNAc-based Drug Market Size, by Rare Liver Disease, 2017-2032 (USD Million)
TABLE 200. United States GalNAc-based Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 201. United States GalNAc-based Drug Market Size, by Clinical Trial Phase, 2017-2032 (USD Million)
TABLE 202. United States GalNAc-based Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 203. Canada GalNAc-based Drug Market Size, 2017-2032 (USD Million)
TABLE 204. Canada GalNAc-based Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 205. Canada GalNAc-based Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 206. Canada GalNAc-based Drug Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 207. Canada GalNAc-based Drug Market Size, by Metabolic Syndrome, 2017-2032 (USD Million)
TABLE 208. Canada GalNAc-based Drug Market Size, by Rare Liver Disease, 2017-2032 (USD Million)
TABLE 209. Canada GalNAc-based Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 210. Canada GalNAc-based Drug Market Size, by Clinical Trial Phase, 2017-2032 (USD Million)
TABLE 211. Canada GalNAc-based Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 212. Mexico GalNAc-based Drug Market Size, 2017-2032 (USD Million)
TABLE 213. Mexico GalNAc-based Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 214. Mexico GalNAc-based Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 215. Mexico GalNAc-based Drug Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 216. Mexico GalNAc-based Drug Market Size, by Metabolic Syndrome, 2017-2032 (USD Million)
TABLE 217. Mexico GalNAc-based Drug Market Size, by Rare Liver Disease, 2017-2032 (USD Million)
TABLE 218. Mexico GalNAc-based Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 219. Mexico GalNAc-based Drug Market Size, by Clinical Trial Phase, 2017-2032 (USD Million)
TABLE 220. Mexico GalNAc-based Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 221. Brazil GalNAc-based Drug Market Size, 2017-2032 (USD Million)
TABLE 222. Brazil GalNAc-based Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 223. Brazil GalNAc-based Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 224. Brazil GalNAc-based Drug Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 225. Brazil GalNAc-based Drug Market Size, by Metabolic Syndrome, 2017-2032 (USD Million)
TABLE 226. Brazil GalNAc-based Drug Market Size, by Rare Liver Disease, 2017-2032 (USD Million)
TABLE 227. Brazil GalNAc-based Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 228. Brazil GalNAc-based Drug Market Size, by Clinical Trial Phase, 2017-2032 (USD Million)
TABLE 229. Brazil GalNAc-based Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 230. United Kingdom GalNAc-based Drug Market Size, 2017-2032 (USD Million)
TABLE 231. United Kingdom GalNAc-based Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 232. United Kingdom GalNAc-based Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 233. United Kingdom GalNAc-based Drug Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 234. United Kingdom GalNAc-based Drug Market Size, by Metabolic Syndrome, 2017-2032 (USD Million)
TABLE 235. United Kingdom GalNAc-based Drug Market Size, by Rare Liver Disease, 2017-2032 (USD Million)
TABLE 236. United Kingdom GalNAc-based Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 237. United Kingdom GalNAc-based Drug Market Size, by Clinical Trial Phase, 2017-2032 (USD Million)
TABLE 238. United Kingdom GalNAc-based Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 239. Germany GalNAc-based Drug Market Size, 2017-2032 (USD Million)
TABLE 240. Germany GalNAc-based Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 241. Germany GalNAc-based Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 242. Germany GalNAc-based Drug Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 243. Germany GalNAc-based Drug Market Size, by Metabolic Syndrome, 2017-2032 (USD Million)
TABLE 244. Germany GalNAc-based Drug Market Size, by Rare Liver Disease, 2017-2032 (USD Million)
TABLE 245. Germany GalNAc-based Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 246. Germany GalNAc-based Drug Market Size, by Clinical Trial Phase, 2017-2032 (USD Million)
TABLE 247. Germany GalNAc-based Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 248. France GalNAc-based Drug Market Size, 2017-2032 (USD Million)
TABLE 249. France GalNAc-based Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 250. France GalNAc-based Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 251. France GalNAc-based Drug Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 252. France GalNAc-based Drug Market Size, by Metabolic Syndrome, 2017-2032 (USD Million)
TABLE 253. France GalNAc-based Drug Market Size, by Rare Liver Disease, 2017-2032 (USD Million)
TABLE 254. France GalNAc-based Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 255. France GalNAc-based Drug Market Size, by Clinical Trial Phase, 2017-2032 (USD Million)
TABLE 256. France GalNAc-based Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 257. Russia GalNAc-based Drug Market Size, 2017-2032 (USD Million)
TABLE 258. Russia GalNAc-based Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 259. Russia GalNAc-based Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 260. Russia GalNAc-based Drug Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 261. Russia GalNAc-based Drug Market Size, by Metabolic Syndrome, 2017-2032 (USD Million)
TABLE 262. Russia GalNAc-based Drug Market Size, by Rare Liver Disease, 2017-2032 (USD Million)
TABLE 263. Russia GalNAc-based Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 264. Russia GalNAc-based Drug Market Size, by Clinical Trial Phase, 2017-2032 (USD Million)
TABLE 265. Russia GalNAc-based Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 266. Italy GalNAc-based Drug Market Size, 2017-2032 (USD Million)
TABLE 267. Italy GalNAc-based Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 268. Italy GalNAc-based Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 269. Italy GalNAc-based Drug Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 270. Italy GalNAc-based Drug Market Size, by Metabolic Syndrome, 2017-2032 (USD Million)
TABLE 271. Italy GalNAc-based Drug Market Size, by Rare Liver Disease, 2017-2032 (USD Million)
TABLE 272. Italy GalNAc-based Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 273. Italy GalNAc-based Drug Market Size, by Clinical Trial Phase, 2017-2032 (USD Million)
TABLE 274. Italy GalNAc-based Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 275. Spain GalNAc-based Drug Market Size, 2017-2032 (USD Million)
TABLE 276. Spain GalNAc-based Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 277. Spain GalNAc-based Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 278. Spain GalNAc-based Drug Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 279. Spain GalNAc-based Drug Market Size, by Metabolic Syndrome, 2017-2032 (USD Million)
TABLE 280. Spain GalNAc-based Drug Market Size, by Rare Liver Disease, 2017-2032 (USD Million)
TABLE 281. Spain GalNAc-based Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 282. Spain GalNAc-based Drug Market Size, by Clinical Trial Phase, 2017-2032 (USD Million)
TABLE 283. Spain GalNAc-based Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 284. China GalNAc-based Drug Market Size, 2017-2032 (USD Million)
TABLE 285. China GalNAc-based Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 286. China GalNAc-based Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 287. China GalNAc-based Drug Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 288. China GalNAc-based Drug Market Size, by Metabolic Syndrome, 2017-2032 (USD Million)
TABLE 289. China GalNAc-based Drug Market Size, by Rare Liver Disease, 2017-2032 (USD Million)
TABLE 290. China GalNAc-based Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 291. China GalNAc-based Drug Market Size, by Clinical Trial Phase, 2017-2032 (USD Million)
TABLE 292. China GalNAc-based Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 293. India GalNAc-based Drug Market Size, 2017-2032 (USD Million)
TABLE 294. India GalNAc-based Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 295. India GalNAc-based Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 296. India GalNAc-based Drug Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 297. India GalNAc-based Drug Market Size, by Metabolic Syndrome, 2017-2032 (USD Million)
TABLE 298. India GalNAc-based Drug Market Size, by Rare Liver Disease, 2017-2032 (USD Million)
TABLE 299. India GalNAc-based Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 300. India GalNAc-based Drug Market Size, by Clinical Trial Phase, 2017-2032 (USD Million)
TABLE 301. India GalNAc-based Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 302. Japan GalNAc-based Drug Market Size, 2017-2032 (USD Million)
TABLE 303. Japan GalNAc-based Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 304. Japan GalNAc-based Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 305. Japan GalNAc-based Drug Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 306. Japan GalNAc-based Drug Market Size, by Metabolic Syndrome, 2017-2032 (USD Million)
TABLE 307. Japan GalNAc-based Drug Market Size, by Rare Liver Disease, 2017-2032 (USD Million)
TABLE 308. Japan GalNAc-based Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 309. Japan GalNAc-based Drug Market Size, by Clinical Trial Phase, 2017-2032 (USD Million)
TABLE 310. Japan GalNAc-based Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 311. Australia GalNAc-based Drug Market Size, 2017-2032 (USD Million)
TABLE 312. Australia GalNAc-based Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 313. Australia GalNAc-based Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 314. Australia GalNAc-based Drug Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 315. Australia GalNAc-based Drug Market Size, by Metabolic Syndrome, 2017-2032 (USD Million)
TABLE 316. Australia GalNAc-based Drug Market Size, by Rare Liver Disease, 2017-2032 (USD Million)
TABLE 317. Australia GalNAc-based Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 318. Australia GalNAc-based Drug Market Size, by Clinical Trial Phase, 2017-2032 (USD Million)
TABLE 319. Australia GalNAc-based Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 320. South Korea GalNAc-based Drug Market Size, 2017-2032 (USD Million)
TABLE 321. South Korea GalNAc-based Drug Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 322. South Korea GalNAc-based Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 323. South Korea GalNAc-based Drug Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 324. South Korea GalNAc-based Drug Market Size, by Metabolic Syndrome, 2017-2032 (USD Million)
TABLE 325. South Korea GalNAc-based Drug Market Size, by Rare Liver Disease, 2017-2032 (USD Million)
TABLE 326. South Korea GalNAc-based Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 327. South Korea GalNAc-based Drug Market Size, by Clinical Trial Phase, 2017-2032 (USD Million)
TABLE 328. South Korea GalNAc-based Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 329. Global GalNAc-based Drug Market Share, by Key Player, 2025
TABLE 330. Global GalNAc-based Drug Market, Key Experts

Companies Mentioned

  • Akcea Therapeutics, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.
  • Arcturus Therapeutics Holdings Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • AstraZeneca plc
  • Bayer AG
  • Beam Therapeutics Inc.
  • BioNTech SE
  • CureVac N.V.
  • Dicerna Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Ionis Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Sarepta Therapeutics, Inc.
  • Takeda Development Center Americas, Inc.
  • Takeda Pharmaceutical Company Limited

Related Topics

Related Reports

GalNAc-siRNA Conjugates Drug Market - Global Forecast 2026-2032 - Product Image

GalNAc-siRNA Conjugates Drug Market - Global Forecast 2026-2032

  • Report
  • 188 Pages
  • Global
From
RNA Therapies - Competitive Landscape, 2026 - Product Image

RNA Therapies - Competitive Landscape, 2026

  • Report
  • 280 Pages
  • Global
From
RNA Therapy Market - Global Forecast 2026-2032 - Product Image

RNA Therapy Market - Global Forecast 2026-2032

  • Report
  • 198 Pages
  • Global
From
Medical Foods for Orphan Diseases - Global Strategic Business Report - Product Image

Medical Foods for Orphan Diseases - Global Strategic Business Report

  • Report
  • 374 Pages
  • Global
From
Prescription Drugs - Global Strategic Business Report - Product Image

Prescription Drugs - Global Strategic Business Report

  • Report
  • 362 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.